Author

Guizhi Zhu

University of MichiganORCID 0000-0002-2945-7982Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Assay:CRISPR screen· 1 Approach:deep learning· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Shurong Zhou· 2 shared Anika Agarwal· 1 shared Arka Sen ChaudhuriiD· 1 shared Bo WeniD· 1 shared Chaofan Li· 1 shared Chunpeng Yang· 1 shared Duxin SuniD· 1 shared Fangming Zhu· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Shurong Zhou

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mechanisms of superior respiratory IgA responses against SARS-CoV-2 after mucosal vaccination

Jinyi Tang, Arka Sen Chaudhuri, Panke Qu, Pei Li, Yajie Liu, Yue Wu, Kristin Wavell, MarthaJoy M. Spano, In Su Cheon, Chaofan Li, Jane Yu, Harish Narasimhan, Mohd Arish, Wei Qian, Gislane de Almeida Santos, , Jie Sun

This study investigates respiratory IgA responses after SARS-CoV-2 infection, vaccination, or hybrid immunity, showing that mucosal booster vaccination enhances IgA and protective immunity.

bioRxiv · Sep 22, 2025 · PreprintImmunology

Engineering circular guide RNA and CRISPR-Cas13d-encoding mRNA for the RNA editing of Adar1 in triple-negative breast cancer immunotherapy

Shurong Zhou, Suling Yang, Jie Xu, Guizhi Zhu

This study develops circular guide RNAs (cgRNAs) and Cas13d-encoding mRNA for efficient RNA editing of Adar1 in triple-negative breast cancer, showing improved stability and therapeutic efficacy.

bioRxiv · Jul 22, 2025 · PreprintBioengineering

Proteolysis-targeting vaccines (PROTAVs) for robust combination immunotherapy of melanoma

Qiyan Wang, Ting Su, Furong Cheng, Shurong Zhou, Xiang Liu, Mi Wang, You Xu, Ri Tang, Shimiao Liao, Jordan M. Dailey, Guolan Xiao, Chunpeng Yang, Hanning Wen, Weijia Zheng, Bo Wen, , Guizhi Zhu

This paper introduces PROTAVs, a new vaccine strategy that enhances T cell responses and combination immunotherapy for melanoma by improving antigen processing and cross-presentation.

bioRxiv · Oct 1, 2024 · PreprintBioengineering